Alexander C Perino, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Perino’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A126531 · Current
Licensed to practise in California · since 2013 · expires 2027-06-30 · University of Colorado School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$309,009
Medicare paid this office $309,009 for 1,101 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 111 | $90,260 | $785 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 83 | $24,677 | $254 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 24 | $17,335 | $693 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 17 | $15,142 | $841 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $12,383 | $106 |
See all 35 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 111 | $90,260 | $785 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 83 | $24,677 | $254 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 24 | $17,335 | $693 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 17 | $15,142 | $841 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $12,383 | $106 |
| Long return visit (40+ min) | 69 | $12,112 | $171 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 27 | $11,928 | $442 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 191 | $11,567 | $24 |
| Insertion of implantable defibrillator system | 15 | $11,558 | $771 |
| New patient visit (60+ min) | 54 | $10,798 | $200 |
| New patient visit (45+ min) | 62 | $9,158 | $148 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 109 | $7,916 | $30 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 25 | $6,360 | $254 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 14 | $5,369 | $384 |
| Return visit (30+ min) | 40 | $5,269 | $120 |
| Long return visit (40+ min) | 38 | $4,330 | $114 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $3,836 | $116 |
| New patient visit (60+ min) | 25 | $3,649 | $146 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 153 | $3,495 | $21 |
| Insertion of tube in left heart chamber through heart septum | 16 | $2,759 | $172 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 307 | $2,631 | $7 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 36 | $2,468 | $63 |
| Programming of dual lead pacemaker system | 62 | $2,308 | $31 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 30 | $2,005 | $22 |
| New patient visit (45+ min) | 15 | $1,676 | $112 |
| Programming of multiple lead implantable defibrillator system | 24 | $1,676 | $52 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,477 | $70 |
| Return visit (30+ min) | 16 | $1,231 | $77 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,080 | $90 |
| Programming of dual lead implantable defibrillator system | 15 | $792 | $49 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 24 | $790 | $32 |
| Programming of heart rhythm stimulation after drug infusion | 13 | $788 | $61 |
| Programming of multiple lead pacemaker system | 13 | $632 | $37 |
| Programming of single lead pacemaker system | 13 | $475 | $26 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 37 | $399 | $11 |
Procedures Medicare counted
| Pacemaker insertion or repair | 60 | More than 92% of doctors who do this |
Who their Medicare patients are
1,101 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 18% · Women 45% · Also on Medicaid 23% · Health risk score 2.07. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 61% · Coronary heart disease 49% · Heart failure 48% · Chronic kidney disease 42% · Diabetes 35% · Depression 24% · Cancer 22% · COPD 18% · Stroke 15% · Dementia 14%.
The office billed $2,647,610, Medicare allowed $394,956 and paid $309,009; for 2,631 services of 75 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,101 | 2,631 | 76 | 2.07 | $2,647,610 | $309,009 |
| 2023 | 1,015 | 2,128 | 75 | 2.20 | $1,804,397 | $229,739 |
| 2022 | 874 | 1,549 | 75 | 2.04 | $1,082,652 | $150,047 |
| 2021 | 543 | 1,183 | 75 | 2.04 | $938,550 | $146,415 |
| 2020 | 88 | 170 | 75 | 1.75 | $204,396 | $31,349 |
| 2016 | 54 | 214 | 77 | 2.94 | $81,662 | $21,656 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 28 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 52 | $45,284 | $823 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 47 | $16,612 | $268 |
| Long return visit (40+ min) | 111 | $16,111 | $127 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 21 | $15,321 | $730 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 33 | $15,000 | $455 |
| Insertion of implantable defibrillator system | 15 | $13,030 | $814 |
| New patient visit (60+ min) | 64 | $10,688 | $167 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 23 | $9,665 | $403 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 156 | $8,177 | $25 |
| New patient visit (45+ min) | 48 | $5,523 | $115 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 89 | $5,208 | $32 |
| Hospital discharge day management, more than 30 minutes | 39 | $4,284 | $104 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 12 | $4,019 | $268 |
| Return visit (30+ min) | 39 | $3,433 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 404 | $3,254 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,181 | $110 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 114 | $2,919 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,481 | $69 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,391 | $120 |
| Programming of dual lead pacemaker system | 51 | $2,221 | $32 |
| Programming of multiple lead implantable defibrillator system | 33 | $2,163 | $53 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 20 | $1,459 | $69 |
| Programming of dual lead implantable defibrillator system | 19 | $916 | $42 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $907 | $76 |
| Programming of heart rhythm stimulation after drug infusion | 11 | $881 | $80 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 19 | $865 | $23 |
| Programming of multiple lead pacemaker system | 12 | $505 | $39 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 28 | $137 | $5 |
2022: 26 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 28 | $29,021 | $967 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 29 | $13,499 | $465 |
| Insertion of implantable defibrillator system | 16 | $13,061 | $816 |
| New patient visit (45+ min) | 64 | $7,646 | $119 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 17 | $6,946 | $409 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 22 | $6,602 | $264 |
| Long return visit (40+ min) | 41 | $5,350 | $124 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 101 | $4,669 | $26 |
| Return visit (30+ min) | 51 | $4,438 | $82 |
| New patient visit (60+ min) | 30 | $4,267 | $142 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 399 | $3,428 | $7 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 50 | $2,787 | $33 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,486 | $124 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 88 | $2,242 | $25 |
| Programming of dual lead pacemaker system | 47 | $1,888 | $33 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,620 | $90 |
| Programming of multiple lead implantable defibrillator system | 22 | $1,551 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,366 | $62 |
| New patient visit (30+ min) | 17 | $1,291 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,211 | $93 |
| Programming of heart rhythm stimulation after drug infusion | 11 | $1,127 | $102 |
| Programming of dual lead implantable defibrillator system | 11 | $791 | $49 |
| Short return visit (20+ min) | 16 | $732 | $46 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $643 | $23 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 15 | $339 | $23 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 16 | $76 | $5 |
2021: 26 services
| Insertion of pacemaker and upper and lower heart chamber electrode | 37 | $16,939 | $458 |
| Insertion of implantable defibrillator system | 19 | $15,810 | $832 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 11 | $10,880 | $989 |
| New patient visit (60+ min) | 61 | $10,161 | $167 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 19 | $7,845 | $413 |
| Long return visit (40+ min) | 51 | $7,166 | $128 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 11 | $5,625 | $375 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 20 | $5,485 | $261 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,835 | $124 |
| Return visit (30+ min) | 32 | $3,155 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,153 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 27 | $2,553 | $91 |
| Programming of dual lead pacemaker system | 49 | $2,456 | $36 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 55 | $2,331 | $26 |
| Programming of multiple lead implantable defibrillator system | 29 | $2,258 | $58 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 16 | $1,947 | $115 |
| New patient visit (45+ min) | 16 | $1,912 | $119 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 73 | $1,837 | $24 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 28 | $1,614 | $34 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,511 | $94 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 147 | $1,396 | $8 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 11 | $1,145 | $104 |
| Short return visit (20+ min) | 13 | $863 | $62 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $420 | $35 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 11 | $240 | $22 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 19 | $216 | $11 |
2020: 3 services
| Long return visit (40+ min) | 16 | $1,652 | $103 |
| Return visit (30+ min) | 13 | $880 | $68 |
| Programming of dual lead pacemaker system | 13 | $583 | $36 |
2016: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $10,833 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,566 | $176 |
| Hospital discharge day management, more than 30 minutes | 31 | $3,112 | $97 |
Medicaid work
$7,418 in 2024
Medicaid paid $7,418 for 469 billed services this clinician did in 2024, up to 112 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 68 | $3,016 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 275 | $2,459 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 100 | $1,494 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 26 | $448 |
| 2024 | 469 | 4 | 112 | $7,418 |
| 2023 | 507 | 3 | 122 | $6,405 |
| 2022 | 327 | 2 | 97 | $3,144 |
| 2021 | 116 | 1 | 104 | $1,116 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 407 | $3,479 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 47 | $2,165 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 53 | $760 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 315 | $2,787 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 12 | $357 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 116 | $1,116 |
Drugs they prescribed that Part D paid
$319,552
Pharmacies billed $319,552 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 649) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
396 generic and 253 brand-name prescriptions · $319,552 in drug cost · 13 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 195 | $257,133 | $1,319 |
| Xarelto | 38 | $43,754 | $1,151 |
| Flecainide Acetate | 36 | $2,389 | $66 |
| Metoprolol | 89 | $1,106 | $12 |
| Sotalol | 32 | $778 | $24 |
See all 9 drugs
| Eliquis | 195 | $257,133 | $1,319 |
| Xarelto | 38 | $43,754 | $1,151 |
| Flecainide Acetate | 36 | $2,389 | $66 |
| Metoprolol | 89 | $1,106 | $12 |
| Sotalol | 32 | $778 | $24 |
| Sucralfate | 69 | $742 | $11 |
| Amiodarone | 18 | $625 | $35 |
| Pantoprazole | 90 | $452 | $5 |
| Metoprolol | 26 | $368 | $14 |
Year by year
| 2024 | 649 | 206 | 0% (0) | 39% | $319,552 |
| 2023 | 565 | 166 | None | 37% | $274,657 |
| 2022 | 421 | 124 | None | 37% | $192,981 |
| 2021 | 214 | 62 | None | 44% | $103,150 |
| 2020 | 25 | 12 | None | None | $8,822 |
| 2016 | 51 | 22 | None | None | $3,222 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Eliquis | 154 | $203,894 | $1,324 |
| Xarelto | 30 | $47,606 | $1,587 |
| Flecainide Acetate | 54 | $3,537 | $65 |
| Dofetilide | 19 | $3,191 | $168 |
| Metoprolol | 70 | $1,245 | $18 |
| Sotalol | 36 | $1,216 | $34 |
| Sucralfate | 62 | $969 | $16 |
| Diltiazem 24hr Er (Cd) | 12 | $557 | $46 |
| Pantoprazole | 49 | $369 | $8 |
| Metoprolol | 35 | $197 | $6 |
2022: 9 drugs
| Eliquis | 104 | $123,106 | $1,184 |
| Xarelto | 31 | $45,461 | $1,466 |
| Dofetilide | 21 | $4,211 | $201 |
| Flecainide Acetate | 32 | $1,960 | $61 |
| Metoprolol | 55 | $1,248 | $23 |
| Sotalol | 38 | $945 | $25 |
| Sucralfate | 37 | $614 | $17 |
| Pantoprazole | 37 | $205 | $6 |
| Metoprolol | 21 | $117 | $6 |
2021: 8 drugs
| Eliquis | 55 | $55,523 | $1,010 |
| Xarelto | 20 | $29,752 | $1,488 |
| Multaq | 14 | $12,806 | $915 |
| Flecainide Acetate | 14 | $2,140 | $153 |
| Metoprolol | 19 | $399 | $21 |
| Sotalol | 14 | $345 | $25 |
| Sucralfate | 18 | $302 | $17 |
| Pantoprazole | 14 | $102 | $7 |
Money from drug and device companies
$31,912 in 2025
| 2025 | 6 | 89 | $23,450 | $31,912 |
| 2024 | 7 | 76 | $10,344 | $19,323 |
| 2023 | 8 | 80 | $10,410 | $18,188 |
| 2022 | 6 | 32 | $3,475 | $5,613 |
| 2021 | 2 | 3 | $750 | $807 |
| 2020 | 3 | 5 | $5,200 | $5,271 |
| 2019 | 8 | 41 | None | $4,382 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biosense Webster | Carto 3 | $10,035 | 33 payments
|
| Boston Scientific | Farapulse | $8,491 | 13 payments
|
| Abbott Laboratories | Merlin@Home | $8,474 | 36 payments
|
| Medical Device Business Services | Carto 3 | $4,050 | 1 payment
|
| Ebr Systems | Wise Crt System | $633 | 4 payments
|
| Medtronic | Affera Mapping System | $230 | 2 payments
|
See all 89 published payments
| Biosense Webster | Meals · 2025-12-18 | Nuvision Ice Catheter | $98 |
| Boston Scientific | Meals · 2025-12-18 | Rhythmia Mapping System | $66 |
| Boston Scientific | Travel · 2025-12-18 | Farapulse | $189 |
| Boston Scientific | Paid to speak or teach · 2025-12-18 | Farapulse | $5,000 |
| Boston Scientific | Paid to speak or teach · 2025-12-18 | Farapulse | $625 |
| Medtronic | Meals · 2025-12-18 | Affera Mapping System | $63 |
| Abbott Laboratories | Meals · 2025-12-16 | Perclose Prostyle | $48 |
| Abbott Laboratories | Consulting · 2025-12-15 | Perclose Proglide | $1,575 |
| Boston Scientific | Meals · 2025-12-07 | Farapulse | $251 |
| Boston Scientific | Travel · 2025-12-06 | Farapulse | $148 |
| Boston Scientific | Travel · 2025-12-06 | Farapulse | $330 |
| Boston Scientific | Meals · 2025-12-06 | Farapulse | $454 |
| Boston Scientific | Meals · 2025-12-06 | Farapulse | $311 |
| Boston Scientific | Travel · 2025-12-05 | Farapulse | $638 |
| Boston Scientific | Travel · 2025-12-05 | Farapulse | $330 |
| Biosense Webster | Consulting · 2025-11-26 | Carto 3 | $1,100 |
| Abbott Laboratories | Travel · 2025-11-21 | Gallant | $713 |
| Biosense Webster | Meals · 2025-11-19 | Carto 3 | $93 |
| Abbott Laboratories | Paid to speak or teach · 2025-11-11 | Merlin@Home | $1,650 |
| Abbott Laboratories | Paid to speak or teach · 2025-11-11 | Merlin@Home | $2,200 |
| Abbott Laboratories | Paid to speak or teach · 2025-11-11 | Merlin@Home | $550 |
| Abbott Laboratories | Travel · 2025-11-11 | Merlin@Home | $58 |
| Abbott Laboratories | Travel · 2025-11-11 | Merlin@Home | $56 |
| Abbott Laboratories | Travel · 2025-11-11 | Merlin@Home | $9 |
| Abbott Laboratories | Meals · 2025-11-06 | Amplatzer Amulet | $26 |
| Abbott Laboratories | Meals · 2025-10-30 | Accent | $157 |
| Biosense Webster | Consulting · 2025-10-27 | Carto 3 | $1,100 |
| Abbott Laboratories | Meals · 2025-10-19 | Merlin@Home | $50 |
| Abbott Laboratories | Meals · 2025-10-19 | Merlin@Home | $23 |
| Abbott Laboratories | Meals · 2025-10-19 | Merlin@Home | $50 |
| Abbott Laboratories | Meals · 2025-10-19 | Merlin@Home | $21 |
| Abbott Laboratories | Meals · 2025-10-18 | Merlin@Home | $54 |
| Abbott Laboratories | Meals · 2025-10-18 | Merlin@Home | $30 |
| Abbott Laboratories | Meals · 2025-10-18 | Merlin@Home | $70 |
| Abbott Laboratories | Meals · 2025-10-18 | Merlin@Home | $18 |
| Abbott Laboratories | Meals · 2025-10-18 | Merlin@Home | $41 |
| Abbott Laboratories | Meals · 2025-10-18 | Merlin@Home | $164 |
| Abbott Laboratories | Travel · 2025-10-18 | Merlin@Home | $221 |
| Abbott Laboratories | Travel · 2025-10-17 | Merlin@Home | $221 |
| Ebr Systems | Meals · 2025-10-08 | None | $148 |
| Abbott Laboratories | Meals · 2025-10-03 | Amplatzer Amulet | $117 |
| Biosense Webster | Consulting · 2025-09-19 | Carto 3 | $1,100 |
| Abbott Laboratories | Meals · 2025-09-19 | Viewmate | $23 |
| Abbott Laboratories | Meals · 2025-09-10 | Ensite Precision | $87 |
| Biosense Webster | Consulting · 2025-08-27 | Carto 3 | $1,125 |
| Biosense Webster | Meals · 2025-08-14 | Carto 3 | $10 |
| Abbott Laboratories | Meals · 2025-08-12 | Viewmate | $24 |
| Abbott Laboratories | Meals · 2025-08-12 | Ensite | $4 |
| Abbott Laboratories | Meals · 2025-08-12 | Ensite | $26 |
| Abbott Laboratories | Meals · 2025-08-12 | Ensite | $7 |
| Biosense Webster | Meals · 2025-07-30 | Carto 3 | $6 |
| Medtronic | Meals · 2025-07-21 | Affera Mapping System | $167 |
| Biosense Webster | Meals · 2025-07-16 | Carto 3 | $133 |
| Ebr Systems | Travel · 2025-07-09 | Wise Crt System | $125 |
| Biosense Webster | Meals · 2025-06-27 | Carto 3 | $147 |
| Biosense Webster | Consulting · 2025-06-24 | Carto 3 | $900 |
| Abbott Laboratories | Meals · 2025-06-16 | Ensite Precision | $96 |
| Biosense Webster | Consulting · 2025-06-10 | Carto 3 | $900 |
| Abbott Laboratories | Meals · 2025-06-02 | Aveir | $17 |
| Abbott Laboratories | Meals · 2025-05-30 | Ensite Precision | $29 |
| Abbott Laboratories | Meals · 2025-05-27 | Perclose Prostyle | $19 |
| Abbott Laboratories | Meals · 2025-05-12 | Aveir | $12 |
| Biosense Webster | Consulting · 2025-05-09 | Carto 3 | $225 |
| Biosense Webster | Meals · 2025-04-26 | Qdot Micro | $16 |
| Boston Scientific | Meals · 2025-04-25 | General - Ep | $73 |
| Ebr Systems | Meals · 2025-04-25 | None | $90 |
| Biosense Webster | Meals · 2025-04-24 | Carto 3 | $110 |
| Biosense Webster | Consulting · 2025-04-24 | Carto 3 | $900 |
| Boston Scientific | Meals · 2025-04-24 | General - Therapies | $75 |
| Biosense Webster | Consulting · 2025-04-17 | Carto 3 | $450 |
| Biosense Webster | Meals · 2025-04-04 | Carto 3 | $12 |
| Abbott Laboratories | Meals · 2025-04-03 | Tacticath Ablation Catheter, Sensor Enabled | $9 |
| Ebr Systems | Meals · 2025-04-01 | None | $270 |
| Biosense Webster | Meals · 2025-03-21 | Carto 3 | $118 |
| Medical Device Business Services | Consulting · 2025-02-12 | Carto 3 | $4,050 |
| Biosense Webster | Travel · 2025-02-06 | Carto 3 | $187 |
| Biosense Webster | Travel · 2025-02-03 | Carto 3 | $35 |
| Biosense Webster | Travel · 2025-02-03 | Carto 3 | $17 |
| Biosense Webster | Travel · 2025-02-03 | Carto 3 | $17 |
| Biosense Webster | Travel · 2025-02-03 | Carto 3 | $289 |
| Biosense Webster | Meals · 2025-02-02 | Carto 3 | $34 |
| Biosense Webster | Meals · 2025-02-02 | Carto 3 | $21 |
| Biosense Webster | Meals · 2025-02-02 | Carto 3 | $9 |
| Biosense Webster | Meals · 2025-02-02 | Carto 3 | $19 |
| Biosense Webster | Meals · 2025-02-02 | Carto 3 | $5 |
| Biosense Webster | Meals · 2025-02-02 | Carto 3 | $33 |
| Biosense Webster | Travel · 2025-02-02 | Carto 3 | $53 |
| Biosense Webster | Meals · 2025-02-01 | Carto 3 | $125 |
| Biosense Webster | Travel · 2025-01-28 | Carto 3 | $647 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $19,323
| Abbott Laboratories | Jot Dx | $7,983 | 39 payments
|
| Biosense Webster | Carto 3 | $6,184 | 17 payments
|
| Medical Device Business Services | Carto 3 | $2,700 | 1 payment
|
| Medtronic | Evera Mri Xt Dr Surescan | $1,124 | 9 payments
|
| Biotronik | Acticor 7 Vr-T Dx | $970 | 5 payments
|
| Boston Scientific | Watchman Access System | $235 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $126 | 1 payment
|
2023: $18,188
| Abbott Laboratories | Gallant | $8,250 | 43 payments
|
| Biosense Webster | Carto 3 | $7,918 | 20 payments
|
| Medical Device Business Services | Carto 3 | $985 | 4 payments
|
| Medtronic | Micra | $759 | 7 payments
|
| Boston Scientific | Watchman Flx | $179 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $46 | 2 payments
|
| iRhythm Technologies | Zio Xt Patch | $38 | 1 payment
|
| Biotronik | Solia | $13 | 1 payment
|
2022: $5,613
| Biotronik | Acticor 7 Vr-T Dx | $3,354 | 14 payments
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $1,007 | 3 payments
|
| Medtronic | Paceart System Ecg Module | $465 | 2 payments
|
| Biosense Webster | Carto 3 | $419 | 4 payments
|
| Boston Scientific | Rhythmia Mapping System | $187 | 6 payments
|
| Abbott Laboratories | Confirm Rx | $181 | 3 payments
|
2021: $807
| Abbott Laboratories | Accent Pacemaker | $790 | 2 payments
|
| Biosense Webster | Carto 3 | $17 | 1 payment
|
2020: $5,271
| E.R. Squibb & Sons L.L.C. | Eliquis | $5,200 | 2 payments
|
| Abbott Laboratories | Ensite Cardiac Mapping System | $57 | 2 payments
|
| Medtronic Vascular | Micra | $14 | 1 payment
|
2019: $4,382
| Boston Scientific | General Therapies | $1,886 | 11 payments
|
| Medical Device Business Services | Carto 3 System | $1,011 | 11 payments
|
| Abbott Laboratories | Ensite Cardiac Mapping System | $828 | 11 payments
|
| Medtronic Vascular | Visia Af | $414 | 4 payments
|
| Biotronik | None | $109 | 1 payment
|
| Janssen Scientific Affairs | Xarelto | $81 | 1 payment
|
| Acist Medical Systems | Cvi Consumables | $33 | 1 payment
|
| Edwards Lifesciences | None | $21 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Abbott Laboratories · Nct06676072--A Study of the Tactiflex Se Catheter and Volt Pfa Generator in Subjects With Paf: · 2025 | Their institution | $134,646 |
| Boston Scientific Corporation · Avant Guard · 2024 | Their institution | $91,542 |
| Boston Scientific Corporation · Avant Guard · 2025 | Their institution | $54,920 |
| Medtronic, Inc. · Leadr Lbbap · 2025 | This clinician | $6,300 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1639435100
- Licence
- CA A126531California A126531: Current · expires 2027-06-30
- Trained
- University of Colorado School of Medicine, Denver, 2012
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-04-09
- NPI last updated
- 2024-04-24
- NPI record certified
- 2024-04-24
This is when the NPI record was last certified, not a medical board exam.